We are live on ! Find out more
NMRA icon

Neumora Therapeutics
NMRA

88 hedge funds and large institutions have $725M invested in Neumora Therapeutics in 2024 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 17 increasing their positions, 18 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

311% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 9

47% more funds holding

Funds holding: 60 → 88 (+28)

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

4.5% more ownership

Funds ownership: 28.67% → 33.17% (+4.5%)

3% less capital invested

Capital invested by funds: $745M → $725M (-$20M)

6% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 18

83% less call options, than puts

Call options by funds: $75K | Put options by funds: $453K

Holders
88
Holders Change
+28
Holders Change %
+46.67%
% of All Funds
1.27%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
37
Increased
17
Reduced
18
Closed
9
Calls
$75K
Puts
$453K
Net Calls
-$378K
Net Calls Change
-$514K

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$57.9M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$17.9M
3
DTC
Deep Track Capital
Connecticut
+$16.2M
4
SCM
Soros Capital Management
New York
+$14.6M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$12.2M

Top Sellers

Rank Fund Capital Flow
1
HA
HHLR Advisors
Cayman Islands
-$29M
2
Goldman Sachs
Goldman Sachs
New York
-$6.95M
3
AI
Alphabet Inc
California
-$6.9M
4
APM
Avidity Partners Management
Texas
-$3.08M
5
GC
GMT Capital
Georgia
-$2.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
SSA
26
Schonfeld Strategic Advisors
New York
$3.42M -$233K -14,405 -5%
CC
27
Callan Capital
California
$2.82M +$3.31M +204,987 New
LP
28
LMR Partners
United Kingdom
$2.58M +$3.04M +187,811 New
Goldman Sachs
29
Goldman Sachs
New York
$2.24M -$6.95M -429,843 -73%
Ensign Peak Advisors
30
Ensign Peak Advisors
Utah
$2.06M – – –
Renaissance Technologies
31
Renaissance Technologies
New York
$1.91M +$2.03M +125,300 +921%
KCM
32
Kennedy Capital Management
Missouri
$1.88M +$2.21M +136,828 New
Millennium Management
33
Millennium Management
New York
$1.88M +$2.21M +136,526 New
Charles Schwab
34
Charles Schwab
California
$1.71M -$86.8K -5,370 -4%
Northern Trust
35
Northern Trust
Illinois
$1.67M -$81.7K -5,053 -4%
TD Asset Management
36
TD Asset Management
Ontario, Canada
$1.52M +$1.78M +110,194 New
Norges Bank
37
Norges Bank
Norway
$1.51M +$970K +60,000 +120%
AA
38
ALPS Advisors
Colorado
$1.48M +$27.8K +1,719 +2%
AI
39
Auour Investments
Massachusetts
$1.44M +$1.7M +105,087 New
Hudson Bay Capital Management
40
Hudson Bay Capital Management
Connecticut
$1.35M +$1.59M +98,300 New
BC
41
BIT Capital
Germany
$1.26M +$1.48M +91,656 New
IC
42
IEQ Capital
California
$1.14M +$1.34M +82,853 New
Citigroup
43
Citigroup
New York
$941K +$1.01M +62,712 +1,091%
LCM
44
Landscape Capital Management
New Jersey
$907K +$1.07M +65,973 New
Morgan Stanley
45
Morgan Stanley
New York
$899K +$52K +3,217 +5%
NFGH
46
Nan Fung Group Holdings
Hong Kong
$871K +$1.02M +63,315 New
Manulife (Manufacturers Life Insurance)
47
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$857K +$1.01M +62,301 New
WCM
48
Wildcat Capital Management
New York
$755K +$887K +54,894 New
Royal Bank of Canada
49
Royal Bank of Canada
Ontario, Canada
$698K +$740K +45,795 +927%
Bank of New York Mellon
50
Bank of New York Mellon
New York
$564K -$67.4K -4,166 -9%
1
2
3 4

NMRA Hedge Fund Activity: Q1 2024 in Review

88 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Neumora Therapeutics (NMRA) for Q1 2024, worth a combined $725M — down 2.7% from $745M a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new NMRA positions and 9 closed out — a net gain of 28 holders — while 17 added to existing stakes and 18 trimmed.

The largest buyer was T. Rowe Price Investment Management, opening a new position worth an estimated $57.9M. The largest seller was HHLR Advisors, exiting entirely with an estimated $29M sold.

  • 88 institutional investors held Neumora Therapeutics (NMRA) as of Q1 2024, up from 60 in Q4 2023.
  • Funds reported $725M of Neumora Therapeutics stock for Q1 2024, down 2.7% quarter-over-quarter.
  • 37 funds opened new Neumora Therapeutics positions in Q1 2024 and 9 closed out, a net change of +28 holders.
  • The largest Neumora Therapeutics buyer in Q1 2024 was T. Rowe Price Investment Management, an estimated $57.9M added.
  • The largest Neumora Therapeutics seller in Q1 2024 was HHLR Advisors, an estimated $29M sold.

Based on aggregated 13F filings for Q1 2024.